Back HCV Treatment Experimental HCV Drugs

Experimental HCV Drugs

AIDS 2014: AbbVie Hepatitis C Treatment Works Well for People on Methadone or Buprenorphine

People with chronic hepatitis C who are using methadone or buprenorphine to manage opiate addiction can be safely and effectively treated with AbbVie's 3D all-oral direct-acting antiviral regimen plus ribavirin, resulting in a 97% cure rate, according to a report this week at the 20thInternational AIDS Conference in Melbourne.People with chronic hepatitis C who are using methadone or buprenorphine to manage opiate addiction can be safely and effectively treated with AbbVie's 3D all-oral direct-acting antiviral regimen plus ribavirin, resulting in a 97% cure rate, according to a report this week at the 20thInternational AIDS Conference in Melbourne.

alt

Read more:

Coverage of the 2014 International AIDS Conference

HIVandHepatitis.com coverage of the 20th International AIDS Conference (AIDS 2014), July 20-25, in Melbourne, Australia.

Conference highlights include biomedical HIV prevention (PrEP and treatment-as-prevention), HIV cure research, interferon-free therapy for hepatitis C and HIV/HCV coinfection, access to treatment, and fighting stigma and criminalization of key affected populations.

Full listing by topic

7/25/14

alt

Interferon-free Daclatasvir + Asunaprevir Approved in Japan for Hepatitis C

Bristol-Myers Squibb's all-oral dual regimen of daclatasvir (Daklinza) plus asunaprevir (Sunvepra) has been approved for the treatment of chronic hepatitis C in Japan, where most people are infected with HCV genotype 1b, the company announced this week.

alt

Read more:

TAG Releases 2014 HIV, Hepatitis C, and Tuberculosis Pipeline Report

The Treatment Action Group (TAG) and HIV i-Base this week released the latest edition of their annual Pipeline Report, covering new therapies and related technologies for HIV, hepatitis C, and tuberculosis (TB), in conjunction with the 20th International AIDS Conference taking place this week in Melbourne, Australia.

alt

Read more:

Survey Finds Most Primary Care Providers Unaware of New Hepatitis C Drugs

Nearly 75% of primary care physicians are unfamiliar with the most recently approved direct-acting antiviral drugs for hepatitis C, and about two-thirds are unaware of even the first-generation antivirals available since 2011, according to a recent survey by Decision Resources Group.

alt

Read more: